Capsular contracture is the most common complication following implant based breast sur gery and is one of the most common reasons for reoperation. Therefore, it is important to try and understand why this happens, and what can be done to reduce its incidence. A literature search using the MEDLINE database was conducted including search terms 'capsular contrac ture breast augmen tation', 'capsular contracture pathogenesis', 'capsular contracture incidence', and 'capsular contracture management', which yielded 82 results which met inclusion criteria. Capsular contracture is caused by an excessive fibrotic reaction to a foreign body (the implant) and has an overall incidence of 10.6%. Risk factors that were identified included the use of smooth (vs. textured) implants, a subglandular (vs. submuscular) placement, use of a silicone (vs. saline) filled implant and previous radio therapy to the breast. The standard management of capsular contracture is surgical via a capsulectomy or capsulotomy. Medical treatment using the offlabel leukotriene receptor antagonist Zafirlukast has been reported to reduce severity and help prevent capsular con tracture from forming, as has the use of acellular dermal matrices, botox and neopocket formation. However, nearly all therapeutic approaches are associated with a significant rate of recurrence. Capsular contracture is a multifactorial fibrotic process the precise cause of which is still unknown. The incidence of contracture developing is lower with the use of textured implants, submuscular placement and the use of polyurethane coated implants. Symptomatic capsular contracture is usually managed surgically, however recent research has focussed on preventing capsular contracture from occurring, or treating it with autologous fat transfer.
INTRODUCTION AND BACKGROUND
Breast augmentation is one of the most commonly performed cosmetic procedures [1] . This commonly involves an implant being inserted within the breast in order to alter the shape and size of the breast. Various types of implant are available and they are generally divided according to the shape of the implant (whe ther rounded or anatomically shaped), or the surface texture (whether smooth or textured) or the gel used to fill the implant (usually either saline or silicone) [2] . Silicone breast implants are currently the most popular and accepted material for use in breast augmentation. These can take one of two forms: a silicone outer shell with a silicone gel filling, or a silicone outer shell with an alternative filling, such as saline [3] . However, the general consensus is that the postsurgical mechanical behaviour of sili cone implants is more like natural breast tissue when compared to saline [4] .
As with any surgery, implant based breast augmentation has been associated with a number of risks and complications. The most common complication is capsular contracture as identi fied in a 25 years longitudinal study by Handel et al. [5] , with implant rupture and malposition also being cited as reasons for reoperation. Introduction of nonbiologic materials into the body always induces formation of a capsule, but in the breast this may be particularly severe. Capsular contracture is a local complication thought to occur due to an excessive fibrotic for eign body reaction to the implant. It is thought to be an inflam matory reaction which causes fibrosis through the production of collagen [3] , leading to excessively firm and painful breasts [6] . If severe enough, this can require reoperation [7] . For an example of how capsular contracture may present (Fig. 1 ).
Capsular contracture is traditionally classified using the Baker classification system, a subjective classification system that is based upon clinical findings in the patient by the physician. It is divided into four classes: I and II are not clinically significant, in that I describes a breast that looks and feels absolutely natural and II describes a breast with minimal contracture in that the surgeon can tell surgery has been performed but there are no symptoms. Class III and IV are clinically significant and symptomatic, with III describing moderate contracture with some firmness felt by the patient and IV describing severe contracture which is obvious from observation and symptomatic in the patient [8] .
Individual studies have published incidence rates of capsular contracture ranging from 2.8% to 20.4% [914] . A recent syste matic review published a combined overall rate of 3.6% follow ing augmentation surgery [2] . However, there is a wide range of heterogeneity between studies in terms of follow up times which may affect capsular contracture development rates, as well as a lack of standardisation in the type of implant and surgical tech niques used. The individual study variables are outlined in Table  1 . Despite the wide range of incidence rates reported, it is widely accepted that capsular contracture is the most common compli cation following implant based breast surgery. Despite this, the aetiology and pathogenesis is not yet clear, although it appears to be multifactorial. In order to effectively treat, or even prevent capsular contracture, it is important to understand the mecha nisms that lead to it.
The aim of this paper is to review the current literature avail able in order to look at the pathogenesis, the risk factors and the optimal management of capsular contracture following breast augmentation surgery.
PATHOGENESIS OF CAPSULAR CONTRACTURE
The pathogenesis of capsular contracture is thought to be multi factorial. It is known that capsular contracture is essentially an excessive fibrotic foreign body reaction that occurs after implan This is a picture of a 40-year-old woman who has Baker grade IV capsular contracture. On the left, the breast is noticeably higher and there is noticeable skin puckering along the medial side. The nipple is higher relative to the right side. tation [6, 15] . Whist on the one hand, this fibrotic reaction helps to maintain the position of the implant, if excessive it can lead to pain and deformity of the breast [16] . The cellular composition of the capsule has been studied ex tensively, and the results seem to suggest a role of the immune system in the pathogenesis of capsular contracture. Macrophages, lymphocytes and fibroblasts have been reported to be the pre dominant cell types within the capsule. Fibroblasts accumulate at the 'contact zone' of the implant and the capsule [6, 17, 18] , and it has been reported that the number of fibroblasts within the capsule correlates with the Baker grade, with an increased number found in grade IV capsular contracture when compared to grade I [19] . As fibroblasts produce collagen, they have been linked to the initial formation of the capsule. Histological evalu ation of capsular tissue has shown that the majority of the tissue is made up of uniformly distributed collagen fibres [3, 19] . The orientation and organisation of the collagen fibres appears to change as contracture severity worsens: the fibres become thick er and establish themselves in cablelike bundles which orien tate themselves perpendicular to the fibroblasts to produce a he lical orientation as the severity increases [20] . The fibroblasts in turn orientate themselves planarly when studied in capsules sur rounding smooth implants [16] .
Mast cells have also been investigated with regards to their in volvement in the pathogenesis of capsular contracture. A study of capsular tissue taken from patients who required revision sur gery or removal of expander found that mast cells within the cap sular tissue expressed renin, histamine and tumour growth fac tor β1 (TGFβ) [19] . Additionally, capsular fibroblasts express corresponding receptors, indicating that the mast cells may acti vate neighbouring fibroblasts via a paracrine pathway following mast cell degranulation, leading to increased production of col lagen and therefore development of capsule contracture.
The role of myofibroblasts in the development of capsule con tracture has also been investigated. Myofibroblasts are contrac tile fibroblasts which are thought to provide a contractile force which decreases the surface area of the capsule whilst the colla gen matrix remodels and stabilises the contracture. Interestingly, these cells have been found to express oestrogen receptorα (ER α) and/or β (ERβ), which are acted on by 17βoestrodiol to increase their contractile force [21] . In the same study, Persichetti et al. [21] investigated the effect of antioestrogenic therapy thr ough administration of Tamoxifen. In the treatment group, there was decreased TGFβ production and myofibroblast contraction, indicating a role of the oestrogen hormones. Therefore, antioes trogenic therapy may help reduce the severity or perhaps prevent capsular contraction from developing. A role of T cells has also been hypothesised. CD4+ T cells have been found to be involved [2225] , with one study finding twice the level of CD4+ cells in those with symptomatic capsular con tracture than those who were asymptomatic asymptomatic [16] , and others showing an increased response in peripheral blood monocytes in response to silicon [24] . It is thought that the CD4+ cells may then produce a specific profibrotic cytokine profile, mediating an immune response by activating TH1 and TH17 cells [16] .
Despite knowing the cells that appear to involved in the pro cess of capsular contracture, it is important to know the way in which they are activated in order to understand how exactly it develops and thus develop strategies to try and prevent it. As well as TGFβ, other molecules that have been associated include tumour necrosis factorα (TNFα), matrix metalloproteinase 2 (MMP2) and its endogenous inhibitors, tissue inhibitors of metalloproteinases 1 and 2 (TIMP1 and TIMP2). TNFα has been reported to be expressed on fibroblasts, macrophages and extracellularly close to the prosthesis, and its presence is associ ated with an increased grade of Baker contracture [17] . Similar ly, MMP2 expression is significantly increased with more se vere grades of Baker classification, with a reduced ratio of MMP to TIMP, a similar scenario as observed in other progressive fi brotic disorders [26] .
Currently, the majority of the literature focuses on the role of TGFβ. A recent study by Katzel et al. [27] indicated that TGFβ may act as a 'master switch' , allowing a cascade of reactions which subsequently leads to capsular contracture. TGFβ signals through the phosphorylation of Smad3. In mice with a knock out of this signalling pathway, capsules were thinner and more regular after being exposed to radiotherapy when compared to controls, which showed thicker capsules made up or irregular collagen. As men tioned previously, women treated with Tamoxifen produced less TGFβ and also had a lower incidence of grade IIIIV capsular contracture than those who were not treated [21] . This may be due to a reduction in oestrogen signalling in myofibroblasts, how ever may also be due to a reduction in activation of fibroblasts by TGFβ [28, 29] . Other immunological agents have also been reported as having a role in the development of capsular contrac ture. These include connective tissue growth factor factor and interleukins 4, 6, 10, 13, and 21 amongst others, all of which pro mote fibrosis [30] . However, more research on their individual roles needs to be conducted before their influence can be fully evaluated. Interleukin8 has been suggested as a potential biomar ker after Kyle et al. [31] reported that it was upregulated along with matrix metallopeptidase 12. This is not the only molecule that has been discussed as a potential biomarker. Wolfram et al. [32] also found that, in those with silicone breast implants, cir culating immune complexes, antipolymer antibodies and solu ble intercellular adhesion molecule1 were also upregulated, and their levels correlated with the development of fibrosis.
Although the majority of current evidence appears to support the role of the immune system, historically it has been suggested that capsular contracture may result from an exaggerated inflam matory response caused by a haematoma or infection. A num ber of studies have found that the presence of bacteria acceler ates contracture development in animal models [33, 34] . In par ticular, the role of coagulase negative staphylococcus species has been investigated with some interest, with a lot of focus on in volvement of Staphylococcus epidermidis, where its presence on implants in animal models has been found to cause increased capsule pressure and a thicker capsule that has an increased den sity of collagen and increased angiogenesis, all of which are sub sequently associated with capsular contracture [33] . However, this theory fails to take into account a number of variables. First ly, capsular contracture does not affect every patient; therefore it is likely that phenotype plays a part in the reaction. Also, this the ory fails to take into account the time lapse often present between surgery and clinically significant contracture development, which can vary greatly. Additionally, prophylactic strategies such as an tibiotic irrigation have failed to show any difference in capsular contracture rates, with reports that washing the implants antis petcially or giving systemic antibiotics having only minor effects, if any [16] . In one study, triple antibiotic breast irrigation was found not to be associated with a significant reduction in the se verity of capsular contracture, with rates published at 3.7% and 3.6% with and without antibiotic irrigation respectively [35] , indicating that biofilm formation may be an incidental finding, rather than a cause and effect in the setting of capsular contrac ture. Additionally, in a porcine experiment, animals which were given implants and inoculated with S. epidermidis did show an increase in the incidence of capsular contracture when compared to those not inoculated, however, there were still incidences of capsular contracture in the noninoculated group [34] . This in dicates that infection, and the subsequent inflammatory response, whilst maybe increasing the rate at which capsular contracture develops does not in fact cause it.
STRATEGIES TO DECREASE THE INCIDENCE OF CAPSULAR CONTRACTURE

Implant choice
There is a wide variety of implants that are available for implant based breast surgery, each of which have slightly different prop erties. These can be broadly separated into whether the surface of the implant is smooth or textured, or whether they are filled with silicone gel or saline and whether the implants are rounded or anatomically shaped. A number of companies provide and develop breast implants, two of the most widely used being Al lergan (Allergan Inc., Los Angeles, CA, USA) and Mentor (Men tor Worldwide LLC., Santa Barabara, CA, USA).
Patients tend to be consulted on the type of implant they would prefer, be that silicone based or saline based, so therefore it is im portant to understand the risks associated with each in order to allow fully informed consent. Silicone gel implants, first intro duced in 1961, currently dominate the world market and this is reflected in the much larger range available for use [36] . In the past, there were concerns with the use of silicone gel implants, especially in the United States of America where their use was restricted to clinical trials up until 2006 due to safety concerns. However, long term studies assessing their safety are currently underway. In terms of the Allergan models, there is both round ed and shaped implants available. A long term multicentre clini cal trial is currently underway assessing the Natrelle Style 410 implant, a form stable highly cohesive shaped model. Results from 3 years reported a capsular contracture rate of 4.8% in pri mary augmentation patients [37] , with results at 6 years echo ing this with a reported rate of 4.6% in the augmentation cohort [38] . A further study reported a 5.6% incidence of capsular con tracture [39] . On the other hand, an ongoing study looking at the use of Mentor round silicone MemoryGel implants in 1,007 women found that the risk of Baker grade III/IV at three years was 8.1% in primary augmentation patients [40] . A similar study looking at shaped Mentor silicone implants reported a 2.4% risk of Baker grade III/IV capsular contracture [41] . Therefore, both suppliers have acceptably low capsular contracture rates with sil icone models and the long term results of these multicentre tri als are likely to have interesting findings. Silicone as a filler mate rial has a number of advantages: it is thought that the implants act more like natural breast tissue and due to extensive develop ment of silicone implants are more technologically innovated. However, saline is still an option for patients.
Saline implants also offer a number of advantages. The main advantage is that saline implants sidestep concerns regarding rup ture of silicone implants. If saline implants rupture, the fluid is absorbed harmlessly into the body, however exposure to silicone gel is thought to be more dangerous [36] . There is less variety available with saline implants and they have remained relatively unchanged over the last few years. In terms of capsular contrac ture risk, a ten year prospective study of the Allergan Natrelle saline filled implants found a 20.8% capsular contracture inci dence in breast augmentation cases [42] , indicating a much a higher risk than with silicone implants. This is in contract to a metaanalysis carried out in 2008 which reported a greater than twofold increased risk of capsular contracture following treat ment with silicone gel implants as opposed to saline. However, these results were limited by the poor scientific qualities of the studies involved and a high variability of the different types of implant used in the various studies [43] . Ideally, more research comparing long term use of saline and silicone implants would be useful or an updated metaanalysis which includes the results of the studies mentioned above in order to evaluate any poten tial difference in capsular contracture risk.
The surface texture of the implant has also been found to have an effect on the incidence of capsular contracture. In terms of the surface of the implant, it has been established that textured implants are associated with a lower risk of clinically significant capsular contracture.as reported by a number of metaanalyses [4446] . Textured implants were introduced following the ob servation that implants covered with polyurethane resulted in a more textured surface, and these had a lower incidence of cap sular contracture [47] . A randomised controlled trial found that, with submuscular placement of the implant, patients had reduc ed symptoms of contracture when a textured implant was used [48] . This finding was supported by a recent risk analysis, which concluded that smooth implants resulted in increased odds of capsular contracture [49] . A systematic review concurred, show ing that using textured implants resulted in the number needed to treat was 8.8 and 6.7 for round and shaped implants respec tively in order to prevent one incidence of Baker grade IIIIV capsular contracture over 10 years [2] . Implants with a macro textured surface were found to significantly decrease the risk of capsule contracture in particular, with participants in one partic ular study finding that when such implants were used, the cap sule mimicked the feeling of natural breast firmness [50] . Re cent research has attempted to link these findings back to patho geneic hypotheses: one recent study found that, in comparison, textured implants were more likely to result in biofilm formation [51] . However, the overall higher incidence rate found with sm ooth implants suggests that biofilm production may not in fact play a large part in capsular contracture development.
Textured implants may be associated with a lower incidence of capsular contracture because of the way in which they interact with the surrounding tissue. The textured surface is thought to disrupt the contractile forces around the implant [16] . Animal studies have found that use of smooth implants led to thicker capsules with an increased concentration of collagen fibres, and additionally had a higher concentration of thick fibres [52] . It has been suggested that macrotextured implants lead to the forma tion of vectors of different lengths and directions, which in turn leads to a more natural breast texture [50] . However, it may ap pear that aggressively textured implants may be associated with other problems, with one study finding a link between the use of textured implants and double capsule formation, which was not seen with smooth implant use [53] . A more thorough under standing of the pathogenesis and development of capsular con tracture at the molecular level would lead to an understanding of how implants interact with the surrounding tissue and therefore help to evaluate the best option in terms of choice of implant.
Polyurethane coated breast implants provide a textured outer surface and have been researched recently due to the reported associated low capsular contracture incidence rates. A recent study by Pompei et al. [54] looked at their use following radio therapy, a recognised risk factor associated with capsular con tracture. They found that capsular contracture occurred in 6.3% of patients who used polyurethane coated implants whereas those who had expanded textured implants inserted reported a rate of 21.7%. Older studies have also found low incidences of capsular contracture. One study looking at their use in breast augmentation found that the incidence of capsular contracture was just 1% [55] . The authors hypothesised that this low rate was due to breakdown of the polyurethane coating causing rem nants of the material to be retained within the capsule causing the collagen fibres to interweave. Histological examination has also found that in capsules surrounding polyurethane implants, there is less fibrotic tissue and less type 3 collagen than seen with textured implants [56] .
Surgical technique
Decisions regarding the procedure have been shown to have an effect on the incidence of capsular contracture. It is commonly accepted that a submuscular placement, where the implant is placed behind the pectoralis major muscle, leads to a lower inci dence of capsular contracture than when the implant is placed just under the skin, in a subglandular placement subglandular [14, 49, 57] . However, both placements can still lead to contrac tion. Siggelkow et al. [3] reported that 21% of patients with sub muscular placement had an increase in Baker grading whereas in those with subglandular placement, 84% noticed an increase. A recent systematic review found that overall rates of capsular con tracture with subglandular placement stood at 8.6%, whereas for submuscular placement it was just 2.8% [2] . However, these findings are not universal, with some studies finding no differ ence between anatomical pocket location and rates of capsule contracture [12] . This suggests that a submuscular placement should be favoured over a subglandular placement in order to re duce future complications. Despite this, a metaanalysis incor porating all the most recent data is required in order to fully eval uate the impact location has on the development of capsule con tracture when taking into account more modern implant models.
MANAGEMENT AND PREVENTION OF CAPSULAR CONTRACTURE: NEW STRATEGIES
Surgical methods
Traditionally, capsular contracture is treated surgically, although it is important to note that treatment is only indicated in grades III and IV capsular contracture. The 'gold standard' treatment has been cited as being a capsulectomy with or without a capsu lotomy [58] with one review finding that these procedures were performed in 3.2% of cases [2] . Two studies found that capsular contraction was the most common reason for reoperation when looking at the safety and efficacy of specific implant models [9, 59] .
Although capsulotomy has been found to be an effective surgi cal treatment for capsular contraction, it tends to recur so there fore multiple procedures may be needed in order to maintain soft breasts [60] . In fact, surgical treatment is associated with a significant risk of contracture recurrence approaching 25% in the first year, which may lead to a cascade of procedures [61] . The most common surgical treatment has been reported to be a total capsulectomy with a site change when indicated [62] , how ever when the contracture has occurred in the submuscular plane this can be difficult and may lead to more complications [63] . A newer surgical management technique has been proposed which involves the formation of a socalled neopocket in which to place the implant. This involves the creation of a new subpec toral plane deep to the pectoralis major muscle but superficial to the anterior capsule, which is left intact to avoid further tissue damage. This allows use of the existing capsule and is usually done through an inframammary incision [64] . A retrospective review of 198 patients, 69.7% of which presented with capsular contracture, who were treated using this technique found a high success rate in reduction of contracture [65] . A further study by Castello et al. [66] concluded that neopocket formation was an effective one stage solution for the correction of augmentation induced deformities, and that complications remained complete ly resolved at 24.1 months followup. This could be a potential new standard of treatment for capsular contracture as allows the use of the existing capsule, but gives a new vascularised pocket in which to insert a new textured implant. However, at present this is only feasible in submuscular placement, as there is enough tissue to allow a new plane to be created.
Other surgical methods which have been discussed as treat ment strategies for capsular contracture include the use of autol ogous fat transfer. This can take one of two forms: lipofilling in order to try and treat capsular contracture or a fat graft placed in the initial procedure along with a half sized implant. There have been some studies that have looked at dual autologous fat trans fer and implant surgery in reconstruction cases which have re ported favourable results. Salgarello et al. [67] found that when fat grafts were used 6 months after radiotherapy followed by im plant placement 3 months later there was a reduced incidence of postoperative complications including capsular contracture at a 15 months followup. These results were echoed in a small study of 28 patients who had lipofilling 6 months after radiotherapy followed by implant placement 3 months later, there was no grade III/IV capsular contracture cases at a 17 months followup [68] . Although these cases have focussed on reconstruction cases, this is a technique that could be adapted for use in primary aug mentation. It would be beneficial to have prospective cohort studies examining this procedure in augmentation cases with long term follow up in order to see if it had an effect on develop ment of capsular contracture.
Additionally, there is recent evidence that suggests autologous fat transfer could be used to treat capsular contracture by increas ing the vascularity of the tissue around the implant. In a study using pigs, they found that although there was no significant dif ference histologically or in Baker grading of the implants, fat in jection did cause the capsule to soften in the treatment group, potentially due to neovascularisation in adjacent tissue [69] . They plan to follow this up in patients with mild to moderate capsule contracture in the future. Unfortunately this is the only study found within our literature search that addresses the use of lipofilling as a treatment of capsular contracture. Therefore, these results will have to be replicated before broad generalisa tions can be made. However, it does show promise for novel sur gical treatments.
Furthermore, the use of acellular dermal matrices has been in vestigated as it is thought that these may alter the reactive pro cesses at the tissueimplant interface, the socalled contact zone and therefore reduce the development of contracture [7073] . In animal studies and small patient populations, this has been shown to have a positive effect. In one study in rats, it was found that the addition of an acellular dermal matrix placed around the implant led to a thinner myofibroblast layer at the contact zone and significantly decreased proliferation and inflammatory signs [71] . The authors hypothesised that this could lead to a reduction in contracture. Similarly, in a patient study which used acellular dermal matrices to prevent capsular contracture, no pa tients in the preventative group developed capsular contracture, leading them to conclude that its use significantly lowers the in cidence of capsular contracture in the first 3.5 years after place ment [73] . When used as a treatment for established capsular contracture, complete acellular dermal matrix coverage has been found to be an effective management strategy in grade III to IV capsular contracture, with no recurrence being seen at a follow up of 9.2 months, in comparison to earlier studies which used partial acellular dermal matrix coverage and found a recurrence of 6.3% [70] . A more recent long term study looked at 127 pa tients who had had a reconstruction with a porcine acellular der mal matrix and reported a capsular contracture incidence of just 0.6% at a mean follow up of 19.6 months, suggesting this may be an effective strategy at preventing or delaying the onset of capsular contracture [74] . Again, like with other proposed man agement strategies, long term studies are needed in a patient pop ulation in order to establish if acellular dermal matrices do in fact prevent capsular contracture, or if they simply delay its onset.
Medical methods
Although the exact eitopathogenesis of capsular contracture re mains to be discerned, the inflammatory response seems to have a role. Therefore, it is thought that altering the inflammatory re sponse through medication may reduce the incidence of capsu lar contracture. The leukotriene antagonist, Zafirlukast (Astro Zeneca) has been used off label to investigate whether it has an effect on the development of contracture. Animal studies have found that when 5 mg/kg per day of Zafirlukast was injected around textured silicone implants, the capsules are thinner and more vascular with a lower collagen density [75, 76] , indicating that the drug may be able to prevent capsular contracture from developing in the first place. A number of studies have also been carried out in women who have undergone implant based sur gery. Generally speaking, although many of the studies have found a reduction in the Baker grading of capsular contraction with a dose of 20 mg twice a day taken orally [7781], however, there was no literature found in patients where Zafirlukast was used as a preventative measure, which may be useful to look at in the fu ture. The most recent research involved a group of 60 patients with mild to severe capsular contracture who were prescribed Zafirlukast for six months. Mammary compliance was assessed before treatment and then monthly up to a year after cessation of treatment. Interestingly, whilst patients were actively taking treatment, contracture grading scores decreased however, on cessation of treatment, grading began to increase again [81] , in dicating that in order to have a long term effect patients would have to continue taking the drug, which could then lead to prob lems with side effects such as adverse effects on the liver. An ear lier study suggested that the beneficial effects of Zafirlukast may be maintained for longer, finding that 73.1% of breasts either im proved or maintained at 16.5 months after the initiation of ther apy [77] . The majority of breasts in this study had mild contrac ture, with 52.8% of participants being graded 2 or under on a modified Baker grading scale, which may explain the more fa vourable results.
Botulinium toxin A has been reported to be effective at reduc ing keloid scarring. Implant capsules have been found to be his tologically similar, so it has recently been investigated to see if it can reduce the amount of contracture or prevent its development. A study in rats which involved injected 0.5 mL (5 units) of botu linium toxin A into implant pockets reported that, in histologi cal analysis of the capsule after 6 weeks, capsular thickness was reduced, there was a decreased number of inflammatory cells and decreased TGFβ1 expression with a loose and well organ ised collagen pattern in the experimental group when compared to control, who were injected with 0.5 mL of saline [82] . A more recent study in mice concurred, also showing reduced expression of TGFβ1 and reduced capsular thickness in treatment groups [83] . It has been suggested that botulinium toxin A may there fore reduce the development of capsular contracture by inter rupting TGFβ1 signalling, subsequently reducing the differen tiation of fibroblasts to myofibroblasts. However, despite prom ising results, more research needs to be carried out before con clusions can be drawn, with a need to evaluate the use of it in pa tient populations.
Antiadhesion barrier solution (AABS) (Guardix, Hanmi Med ical Co., Seoul, Korea) has also been studied with regards to its effect at reducing the development of capsular contracture. Ani mal studies have showed promising results. A study in rats that looked at the use of AABS and compared to a control group and to a fibrin treated group found that, in treatment groups, there were thinner capsules and significantly decreased amount of type 1 collagen compared to controls, but that there was no signifi cant difference between the AABS group and the fibrin treated group [84] . Moreover, another group reported that the use of 0.1 mL AABS with silicone blocks in rates led to a significantly decreased inflammatory cell count and capsular thickness when compared to controls after 4 weeks [85] . Furthermore, a rabbit study which kept the implants in situ for 2 months following AA BS treatment reported that, although there was no significant difference in capsule thickness or contracture on gross analysis, histologically the capsules were thinned and had a lower density of collagen and a lower ratio of myofibroblasts when compared to controls [86] . Although these results seem promising, there is currently no long term data, and clinical trials would need to be conducted in the future in order to evaluate if these results can be replicated in a patient population.
ANAPLASTIC LARGE CELL LYMPHOMA
Another risk associated with the use of implants is the possibili ty of anaplastic large cell lymphoma (ALCL). This is a rare type of nonHodgkin's lymphoma and most cases occur in the cap sule surrounding the implant and it is thought to be potentially associated with prolonged inflammatory states, similar to the theoretical pathogenesis of capsular contracture. A recent review concluded that there was a relative risk of 18.2 that ALCL would occur in women with breast implants compared to those with out implants when looking at the 71 case studies published at the time, however the absolute risk remains low, ranging from 1:500,000 to 1:3,000,000 [87] . These figures are yet to be con firmed with further studies, and it is possible that they may change in light of updated numbers of case reports and increased global awareness of the disease. It is important to note that most patients who had disease confined to the implant capsule have a good prognosis, with the majority achieving complete remission [88] .
For an example of the histological appearance of ALCL associ ated with implants (Fig. 2) . The overall incidence is quite low, estimated to be 1 in 1 million per year [89] , however women who develop this condition may present with capsular contrac ture and an effusion within the capsule. Alternatively, women may also present with an effusion and a mass lesion. Interesting ly, those who present with effusion with or without capsular contracture have a better prognosis than those presenting with a mass [90] . Recurrent capsule contracture has been identified as a possible independent presenting symptom in those with ALCL, and possibly capsular contracture occurring years after the first surgery which appears to refractory to usual management tech niques [91] . This should be borne in mind when assessing a pa tient with capsular contracture, as earlier treatment may lead to 
CONCLUSIONS
Capsular contracture is the most common complication follow ing breast augmentation surgery. This literature review has at tempted to outline some of the recent research regarding capsu lar contracture after breast augmentation surgery in order to iden tify risk factors and potential management strategies. From the current literature, it would appear that capsular contracture is a multifactorial process which involves inflammatory processes which then cause a fibrotic reaction in the tissue surrounding the implant, although the precise trigger and the reason why this happens is still not clear. Despite this, risk factors have been iden tified. From the currently available research, it appears that smooth implants, paced in a subglandular position have the biggest risk of developing capsular contracture.
Medical treatment of symptomatic cases seems to be ineffec tive and surgical therapy is associated with a significant rate of recurrence. However, there is a flurry of promising new research attempting to elucidate new management strategies or prophy lactic strategies attempting to stop capsular contracture before it begins. Of these, the use of acellular dermal matrices has received the most attention, but new research looking at autologous fat transfer or using implants with lower incidence rates such as those coated in polyurethane shows promising results. More re search in these areas needs to be undertaken in order to find the best possible method at avoiding reoperation and explantation.
The results of this review can add to current clinical practice by providing more information to women about the risks re garding breast augmentation surgery and help towards fully in formed consent. In the future, it is recommended that a thor ough metaanalysis is carried out which takes into account all the factors that can affect the incidence of capsular contracture: the anatomical placement of the implant, the surface texture of the implant and the core type of the implant as well as a history of radiotherapy to the breast. Reconstruction and radiotherapy have been identified as independent risk factors for capsular con tracture, and more research should be carried out in order to es tablish the amount of risk conferred. In addition, new strategies for preventing and treating capsular contracture need to be eval uated in large patient population studies in order to evaluate their real life benefits. Due to findings that the immune system is in volved in the pathogenesis, future research should also focus on the possibility of biological profiling in order to identify women at an increased risk of capsular contraction and therefore offer them the best possible treatment with the lowest possible risk.
